PE20091069A1 - Derivados de pirazol como inhibidores de 5-lo - Google Patents
Derivados de pirazol como inhibidores de 5-loInfo
- Publication number
- PE20091069A1 PE20091069A1 PE2008001974A PE2008001974A PE20091069A1 PE 20091069 A1 PE20091069 A1 PE 20091069A1 PE 2008001974 A PE2008001974 A PE 2008001974A PE 2008001974 A PE2008001974 A PE 2008001974A PE 20091069 A1 PE20091069 A1 PE 20091069A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- methyl
- och3
- derivatives
- pyran
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 abstract 3
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 abstract 1
- 101000790711 Chlamydomonas reinhardtii Uncharacterized membrane protein ycf78 Proteins 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- DGOYLVBDCVINQZ-UHFFFAOYSA-N oxane-4-carboxamide Chemical compound NC(=O)C1CCOCC1 DGOYLVBDCVINQZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Abstract
SE REFIERE A DERIVADOS DE PIRAZOL DE FORMULA (I), DONDE Q ES -S- O -S(O)-; X E Y SON CADA UNO C, N; L ES ENLACE, -(CH2)-, -O-, ENTRE OTROS; R1 Y R2 SON CADA UNO H, METILO, ETILO; R3 ES -CN, -C(O)NH2, -C(O)NH2, -C(O)NH(CH3); R4 ES H, HALO; R5 ES H, HALO -CN, -OCH3; R6 ES H, HALO, -CN; R7 ES HALO, -CN, METILO, -OCH3; R8 ES H, HALO, -OCH3, ENTRE OTROS; R9 ES -CN, METILO, CF3, ENTRE OTROS; R10 ES H, -CN, HALO; R11 ES H, ALQUILO C1-C7; R12 ES H, HALO. SON COMPUESTOS PREFERIDOS: 4-[3-({5-CLORO-6-[(1-METIL-1H-PIRAZOL-5-IL)OXI]PIRIDIN-3-IL}TIO)FENIL]TETRAHIDRO-2H-PIRAN-4-CARBOXAMIDA; (2S,4R)-4-[3-({5-CLORO-6-[(1-METIL-1H-PIRAZOL-5-IL)OXI]PIRIDIN-3-IL)TIO}-2-FLUOROFENIL]-2-METILTETRAHIDRO-2H-PIRAN-4-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA SU PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO TIENE ACTIVIDAD INHIBITORIA DE 5-LIPOXIGENASA (5-LP), SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIA MEDIADAS POR 5-LP TAL COMO EL ASMA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US423607P | 2007-11-26 | 2007-11-26 | |
| US426107P | 2007-11-26 | 2007-11-26 | |
| US5549708P | 2008-05-23 | 2008-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091069A1 true PE20091069A1 (es) | 2009-07-19 |
Family
ID=40568336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001974A PE20091069A1 (es) | 2007-11-26 | 2008-11-25 | Derivados de pirazol como inhibidores de 5-lo |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8097733B2 (es) |
| EP (1) | EP2225229A1 (es) |
| JP (1) | JP4718650B2 (es) |
| KR (1) | KR20100072090A (es) |
| CN (1) | CN101918392A (es) |
| AP (1) | AP2010005269A0 (es) |
| AR (1) | AR069743A1 (es) |
| AU (1) | AU2008331199A1 (es) |
| BR (1) | BRPI0819661A2 (es) |
| CA (1) | CA2705729C (es) |
| CL (1) | CL2008003495A1 (es) |
| CO (1) | CO6280402A2 (es) |
| CR (1) | CR11392A (es) |
| DO (1) | DOP2010000155A (es) |
| EA (1) | EA201000703A1 (es) |
| EC (1) | ECSP10010200A (es) |
| IL (1) | IL205602A0 (es) |
| MA (1) | MA31863B1 (es) |
| MX (1) | MX2010004604A (es) |
| NI (1) | NI201000089A (es) |
| PA (1) | PA8805301A1 (es) |
| PE (1) | PE20091069A1 (es) |
| SV (1) | SV2010003579A (es) |
| TN (1) | TN2010000231A1 (es) |
| TW (1) | TW200927098A (es) |
| UY (1) | UY31487A1 (es) |
| WO (1) | WO2009069044A1 (es) |
| ZA (1) | ZA201002758B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5351254B2 (ja) | 2008-05-23 | 2013-11-27 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| WO2011137363A1 (en) * | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
| WO2011161615A1 (en) | 2010-06-24 | 2011-12-29 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| CA2919552C (en) * | 2013-07-29 | 2022-03-15 | Merck Patent Gmbh | 1,3-disubstituted cyclopentane derivatives |
| GB201403605D0 (en) * | 2014-02-28 | 2014-04-16 | Mologic Ltd | Monitoring inflammation status |
| BR122020001830B1 (pt) | 2015-05-18 | 2023-02-28 | Shenyang Sinochem Agrochemicals R&D Co., LTD | Compostos pirazol substituídos contendo pirimidinila, preparação e aplicação dos mesmos |
| CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
| WO2021252951A1 (en) | 2020-06-12 | 2021-12-16 | Vanderbilt University | Methods of treatment for gastrointestinal motility disorders |
| AU2021389685A1 (en) * | 2020-11-25 | 2023-07-06 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cd73 inhibitors and pharmaceutical uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254581A (en) | 1990-06-21 | 1993-10-19 | Imperial Chemical Industries Plc | Pyran derivatives and their use as inhibitors of 5-lipoxygenase |
| US5272173A (en) | 1990-11-28 | 1993-12-21 | Imperial Chemical Industries Plc | 5-lipoxygenase inhibitors |
| IE913866A1 (en) | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
| GB9300894D0 (en) | 1992-02-07 | 1993-03-10 | Zeneca Ltd | Oxime derivatives |
| US6063928A (en) | 1994-10-18 | 2000-05-16 | Pfizer Inc | 5-lipoxygenase inhibitors |
| US5883106A (en) | 1994-10-18 | 1999-03-16 | Pfizer Inc. | 5-lipoxygenase inhibitors |
| SK281577B6 (sk) * | 1994-10-18 | 2001-05-10 | Pfizer Inc. | Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze |
| JP3400392B2 (ja) * | 1994-10-18 | 2003-04-28 | ファイザー製薬株式会社 | ５−リポキシゲナーゼ阻害剤及び新規医薬組成物 |
| US6239285B1 (en) | 1998-02-06 | 2001-05-29 | Pfizer Inc | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| WO2007087250A2 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| EP1834953A1 (en) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
| BRPI0718672A2 (pt) * | 2006-11-27 | 2013-11-26 | Pfizer Prod Inc | Análogos de pirazol |
-
2008
- 2008-11-20 CN CN2008801178682A patent/CN101918392A/zh active Pending
- 2008-11-20 AP AP2010005269A patent/AP2010005269A0/en unknown
- 2008-11-20 MX MX2010004604A patent/MX2010004604A/es not_active Application Discontinuation
- 2008-11-20 EA EA201000703A patent/EA201000703A1/ru unknown
- 2008-11-20 WO PCT/IB2008/054873 patent/WO2009069044A1/en not_active Ceased
- 2008-11-20 KR KR1020107011376A patent/KR20100072090A/ko not_active Ceased
- 2008-11-20 BR BRPI0819661A patent/BRPI0819661A2/pt not_active IP Right Cessation
- 2008-11-20 CA CA2705729A patent/CA2705729C/en not_active Expired - Fee Related
- 2008-11-20 JP JP2010535484A patent/JP4718650B2/ja not_active Expired - Fee Related
- 2008-11-20 EP EP08853504A patent/EP2225229A1/en not_active Withdrawn
- 2008-11-20 AU AU2008331199A patent/AU2008331199A1/en not_active Abandoned
- 2008-11-24 CL CL2008003495A patent/CL2008003495A1/es unknown
- 2008-11-24 US US12/276,779 patent/US8097733B2/en not_active Expired - Fee Related
- 2008-11-25 UY UY31487A patent/UY31487A1/es not_active Application Discontinuation
- 2008-11-25 TW TW097145472A patent/TW200927098A/zh unknown
- 2008-11-25 PE PE2008001974A patent/PE20091069A1/es not_active Application Discontinuation
- 2008-11-26 PA PA20088805301A patent/PA8805301A1/es unknown
- 2008-11-26 AR ARP080105131A patent/AR069743A1/es not_active Application Discontinuation
-
2010
- 2010-04-20 ZA ZA2010/02758A patent/ZA201002758B/en unknown
- 2010-04-26 CR CR11392A patent/CR11392A/es not_active Application Discontinuation
- 2010-05-06 IL IL205602A patent/IL205602A0/en unknown
- 2010-05-21 TN TN2010000231A patent/TN2010000231A1/fr unknown
- 2010-05-24 DO DO2010000155A patent/DOP2010000155A/es unknown
- 2010-05-25 NI NI201000089A patent/NI201000089A/es unknown
- 2010-05-26 CO CO10063358A patent/CO6280402A2/es not_active Application Discontinuation
- 2010-05-26 MA MA32869A patent/MA31863B1/fr unknown
- 2010-05-26 SV SV2010003579A patent/SV2010003579A/es not_active Application Discontinuation
- 2010-05-26 EC EC2010010200A patent/ECSP10010200A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4718650B2 (ja) | 2011-07-06 |
| CA2705729A1 (en) | 2009-06-04 |
| ECSP10010200A (es) | 2010-06-29 |
| IL205602A0 (en) | 2010-11-30 |
| DOP2010000155A (es) | 2010-07-15 |
| CR11392A (es) | 2010-05-28 |
| AR069743A1 (es) | 2010-02-17 |
| US20090227634A1 (en) | 2009-09-10 |
| MX2010004604A (es) | 2010-08-04 |
| MA31863B1 (fr) | 2010-11-01 |
| CL2008003495A1 (es) | 2010-03-12 |
| UY31487A1 (es) | 2009-07-17 |
| AU2008331199A1 (en) | 2009-06-04 |
| CO6280402A2 (es) | 2011-05-20 |
| SV2010003579A (es) | 2011-03-23 |
| EA201000703A1 (ru) | 2010-12-30 |
| NI201000089A (es) | 2010-10-05 |
| CA2705729C (en) | 2012-09-18 |
| PA8805301A1 (es) | 2009-06-23 |
| TW200927098A (en) | 2009-07-01 |
| EP2225229A1 (en) | 2010-09-08 |
| TN2010000231A1 (fr) | 2011-11-11 |
| US8097733B2 (en) | 2012-01-17 |
| AP2010005269A0 (en) | 2010-06-30 |
| KR20100072090A (ko) | 2010-06-29 |
| JP2011504514A (ja) | 2011-02-10 |
| ZA201002758B (en) | 2011-06-29 |
| CN101918392A (zh) | 2010-12-15 |
| WO2009069044A1 (en) | 2009-06-04 |
| BRPI0819661A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| PE20180177A1 (es) | Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
| PE20130311A1 (es) | Composiciones y metodos para modular la via de senalizacion de wnt | |
| PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| JO2910B1 (en) | Organic compounds | |
| PE20060241A1 (es) | 2-quinolil-oxazoles sustituidos como inhibidores de pde4 | |
| PE20080418A1 (es) | Compuestos y composiciones como moduladores de la via de hedgehog | |
| NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
| PE20142099A1 (es) | Derivados de sulfonamida | |
| SV2009003233A (es) | Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20091096A1 (es) | Compuestos organicos | |
| PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal | |
| PE20110150A1 (es) | Amidofenoxiindazoles como inhibidores de c-met | |
| TW200722086A (en) | Compounds comprising an oxazole or thiazole moiety, processes for making them and their uses | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20080453A1 (es) | Derivados de fenil.oxi-fenil-pirimidinona en el tratamiento de malaria | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |